Clinical Phase I Study of the Hypoxic Cell Radiosensitizer RO-07-0582, A 2-Nitroimidazole Derivative

Authors:
  • RURaul C. Urtasun
    Raul C. Urtasun
  • PBPierre Band
    Pierre Band
  • JCJ. Donald Chapman
    J. Donald Chapman
  • HRHarvey R. Rabin
    Harvey R. Rabin
  • AWA. Fred Wilson
    A. Fred Wilson
  • CFCarol G. Fryer
    Carol G. Fryer
Publisher website
Google Scholar
Abstract
RO-07-0582 toxicity studies were performed in 12 patients for a total of 16 assays. Single and multifraction dose schedules were used, and drug concentrations in solid tumor tissue, cerebrospinal fluid, and blood (at 14 to 24 hr.) were established. A severe peripheral neuropathy occurred in 1 patient on the multifraction regimen when the total dosage reached 24 g. Drug absorption and concentration in the blood do not significantly differ from that of metronidazole. Maximum blood levels were reached at from 2 to 4 hr., and several days subsequent to administration had stabilized to levels only slightly above control levels.